ADMA Biologics Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.89 (market cap $2.22B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.89. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | JNK | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Fixed Income |
52-Week High | $20.38 | $98.19 |
52-Week Low | $7.60 | $94.66 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
JNK trades at $95.845, up 0.2% today, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights risks from AI-related corporate debt and rising Treasury yields, while dividend payments provide income. The ETF faces headwinds from inflation and geopolitical tensions affecting bond markets.
The outlook is cautious due to credit market risks and Fed uncertainty. Opportunities exist for yield-seeking investors, but volatility from oil prices and rate hikes poses significant risks. Monitoring economic data and corporate credit health is essential for navigating near-term performance.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →